Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rivaroxaban

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Rivaroxaban. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2019-000267-25 Sponsor Protocol Number: STH20412 Start Date*: 2020-03-17
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Characterisation of a novel regimen of very low-dose aspirin combined with rivaroxaban in patients with chronic coronary syndromes: WILL lOWer dose aspirin be better with rivaroxaban in patients wi...
    Medical condition: Chronic coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005523-27 Sponsor Protocol Number: CIRROXABAN Start Date*: 2015-07-30
    Sponsor Name:INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
    Full Title: Multicenter prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis
    Medical condition: Liver cirrhosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017313-30 Sponsor Protocol Number: BAY59-7939/12892 Start Date*: 2010-06-04
    Sponsor Name:Bayer HealthCare AG
    Full Title: Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism
    Medical condition: Venous thromboembolism.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) IT (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004449-40 Sponsor Protocol Number: BAY 59-7939/11898 Start Date*: 2007-02-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with...
    Medical condition: Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BE (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) SK (Completed) GB (Completed) BG (Completed) FI (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005569-58 Sponsor Protocol Number: BAY59-7939/17454 Start Date*: 2015-09-23
    Sponsor Name:Bayer AG
    Full Title: An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular event...
    Medical condition: Peripheral artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10053375 Peripheral revascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) ES (Completed) HU (Completed) GB (Completed) FR (Completed) PT (Completed) SE (Completed) BE (Completed) BG (Completed) DK (Completed) DE (Completed) NL (Completed) PL (Completed) SK (Completed) LT (Completed) LV (Completed) RO (Completed) EE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004494-96 Sponsor Protocol Number: BAY 59-7939/IMP 11899 Start Date*: 2007-03-19
    Sponsor Name:Bayer HealthCare AG
    Full Title: Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emb...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) DE (Completed) FI (Completed) FR (Completed) HU (Completed) AT (Completed) IT (Completed) DK (Completed) CZ (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002708-25 Sponsor Protocol Number: RIVAROXACS3001 (BAY59-7939/13194) Start Date*: 2008-11-27
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome The ATLAS ACS 2 ...
    Medical condition: Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) DE (Completed) PT (Completed) SK (Completed) HU (Completed) FR (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) IT (Completed) LV (Completed) CZ (Completed) BG (Completed) BE (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002385-74 Sponsor Protocol Number: BAY59-7939/17618 Start Date*: 2015-04-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: 7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with catheter-related arterial or venous ...
    Medical condition: Catheter related venous or arterial thrombosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) NL (Completed) PL (Completed) FR (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003303-31 Sponsor Protocol Number: BAY59-7939/13238 Start Date*: 2009-01-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer.
    Medical condition: Patients with acute, proximal DVT or acute PE who concomitantly use a strong CYP 3A4 inducer for the entire 3-month study duration.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000619-26 Sponsor Protocol Number: BAY59-7939/16416 Start Date*: 2014-06-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037439 Pulmonary thrombotic and embolic conditions HLT
    14.1 10047065 - Vascular disorders 10034572 Peripheral embolism and thrombosis HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) NL (Completed) NO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002263-96 Sponsor Protocol Number: 39486 Start Date*: 2012-07-11
    Sponsor Name:MUMC
    Full Title: dabigatran and rivaroxaban: prediction of anticoagulant effect
    Medical condition: non valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003679-20 Sponsor Protocol Number: DUAL-PAD_v3 Start Date*: 2020-03-11
    Sponsor Name:Radboudumc
    Full Title: DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease (PAD)
    Medical condition: symptomatic or stable pheripheral artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004484-31 Sponsor Protocol Number: Riva-PCC Start Date*: 2014-01-10
    Sponsor Name:Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin
    Full Title: Rivaroxaban and PCC: Prothrombin Complex Concentrate in patients with bleeding complications related to Rivaroxaban
    Medical condition: blood coagulation disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10009728 Coagulation and bleeding analyses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000958-36 Sponsor Protocol Number: RIDTS-Vers3-20Jan2016 Start Date*: 2016-08-18
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
    Full Title: RIDTS Study - Rivaroxaban for the treatment of symptomatic Isolated Distal deep vein Thrombosis
    Medical condition: SYMPTOMATIC ISOLATED DISTAL DEEP VEIN THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10049915 Deep venous thrombosis distal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001053-44 Sponsor Protocol Number: Carotis-Rivaroxaban_CEUS_001 Start Date*: 2020-09-30
    Sponsor Name:Rigshospitalet, Department of Vascular Surgery
    Full Title: Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS)
    Medical condition: Patients with - Stable peripheral artery disease and - Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10075495 Internal carotid artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004180-43 Sponsor Protocol Number: BAY59-7939/15786 Start Date*: 2013-03-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People u...
    Medical condition: Prevention of major cardiovascular events in patients with coronary or peripheral artery disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10064939 Cardiovascular event prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) CZ (Completed) FI (Completed) IT (Completed) HU (Completed) NL (Completed) GB (Completed) SK (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000565-47 Sponsor Protocol Number: BAY59-7939/14372 Start Date*: 2014-07-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with...
    Medical condition: Venous Thrombosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) IE (Completed) FR (Completed) FI (Completed) HU (Completed) SE (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000305-13 Sponsor Protocol Number: RIVAROXDVT3002/BAY59-7939/17261 Start Date*: 2014-07-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
    Medical condition: Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) IT (Completed) ES (Completed) NL (Completed) LT (Completed) BG (Completed) GR (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001975-30 Sponsor Protocol Number: BAY59-7939/17938 Start Date*: 2016-01-12
    Sponsor Name:Bayer AG
    Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ...
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000648-16 Sponsor Protocol Number: BAY59-7939/19365 Start Date*: 2017-06-21
    Sponsor Name:Bayer AG
    Full Title: Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects
    Medical condition: Prevention and treatment of thromboembolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10043640 Thrombosis venous LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 00:01:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA